CVM - CEL-SCI Corporation

NYSE American - NYSE American Delayed Price. Currency in USD

CEL-SCI Corporation

8229 Boone Boulevard
Suite 802
Vienna, VA 22182
United States

Full Time Employees

Key Executives

Mr. Geert R. Kersten Esq.Chief Exec., Financial & Accounting Officer and Director613.41kN/A58
Ms. Patricia B. PrichepSr. VP of Operations & Corp. Sec.254.84kN/A66
Dr. Eyal Talor Ph.D.Chief Scientific Officer309.63kN/A61
Dr. Daniel H. Zimmerman Ph.D.Sr. VP of Research - Cellular Immunology234.44kN/A76
Mr. John CiprianoSr. VP of Regulatory Affairs211.44kN/A75
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The company’s Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.

Corporate Governance

CEL-SCI Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.